Hengrui Medicine Granted Approval to Market Cancer Drug in US

Jiangsu Hengrui Medicine was approved by the FDA for US marketing of oxalipatin, a generic treatment for colon and rectum cancer. Hengrui, whose major focus is chemotherapies, has annual revenues of $1 billion. The company said the latest US approval is part of its globalization initiative. Hengrui already markets oxalipatin in China and Europe. More details.... Stock Symbol: (SHA: 600276) Share this with colleagues: // //